A Phase 1 Thorough QT/QTc Study of Therapeutic and Supratherapeutic Doses of Belumosudil in Healthy Subjects
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1142
Abstract: Belumosudil is a selective Rho‐associated, coiled‐coil‐containing protein kinase‐2 inhibitor. In this crossover design thorough QT/QTc study, single therapeutic (200 mg) and supratherapeutic (1000 mg) oral doses of belumosudil, moxifloxacin (positive control), and placebo were administered… read more here.
Keywords: effect; therapeutic supratherapeutic; thorough qtc; doses belumosudil ... See more keywords